ArticleInternational journal of clinical oncology2026
Pharmacotherapy for older adults with cancer: a digest of the Japanese clinical practice guidelines (2nd edition)-gastrointestinal cancers.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe number of older adults with gastrointestinal cancers is increasing in rapidly aging societies. However, optimal pharmacotherapy for this population remains challenging because of heterogeneity in functional status, comorbidities, and the limited representation of older patients in clinical trials.
methodsThis article presents an English digest of the Japanese Clinical Practice Guidelines for Pharmacotherapy in Older Adults with Cancer (second edition) [5] with a focus on gastrointestinal cancers. The guidelines were developed in accordance with the Minds 2020 methodology, incorporating systematic reviews, the Evidence-to-Decision framework, and multidisciplinary consensus.
resultsThe guideline addresses key clinical questions regarding systemic therapy for older patients with gastric and colorectal cancers, including combination chemotherapy, biomarker-guided therapy, and adjuvant treatment strategies. All recommendations were conditional because of limited direct evidence in older populations. Specifically, in gastric cancer, oxaliplatin-containing combination therapy and biomarker-guided treatment may be considered for appropriately selected patients and are conditionally recommended. In colorectal cancer, routine treatment intensification with oxaliplatin- or irinotecan-containing regimens is not uniformly recommended. Treatment decisions should be individualized by weighing the expected benefit against the risk of increased toxicity, particularly in frail or very old patients.
conclusionsThese guidelines provide practical evidence-informed recommendations for pharmacotherapy in older adults with gastrointestinal cancers. They emphasize individualized treatment strategies that integrate patient characteristics, treatment goals, and tolerability. Further research, specifically targeting older populations, is required to strengthen the evidence base in geriatric oncology.
Indexed as
Identifiers
42789150What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.